Similar articles

• Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.

  Packer M, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller C, George J, Brueckmann M, Anker SD, Zannad F; EMPEROR-Reduced Trial Committees and Investigators. Packer M, et al. Eur J Heart Fail. 2019 Oct;21(10):1270-1278. doi: 10.1002/ejhf.1536. Epub 2019 Jul 16. Eur J Heart Fail. 2019. PMID: 31584231
• Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced.

  Ferreira JP, Zannad F, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Jamal W, Steubl D, Schueler E, Packer M. Ferreira JP, et al. J Am Coll Cardiol. 2021 Mar 23;77(11):1397-1407. doi: 10.1016/j.jacc.2021.01.044. J Am Coll Cardiol. 2021. PMID: 33736821 Clinical Trial.
• Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.

  Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Sattar N, Brueckmann M, Jamal W, Cotton D, Iwata T, Zannad F; EMPEROR-Reduced Trial Committees and Investigators. Packer M, et al. J Am Coll Cardiol. 2021 Mar 23;77(11):1381-1392. doi: 10.1016/j.jacc.2021.01.033. J Am Coll Cardiol. 2021. PMID: 33736819 Clinical Trial.
• Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice.

  Rosano G, Quek D, Martínez F. Rosano G, et al. Card Fail Rev. 2020 Nov 13;6:e31. doi: 10.15420/cfr.2020.23. eCollection 2020 Mar. Card Fail Rev. 2020. PMID: 33294215 Free PMC article. Review.
• Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Non-Diabetic Chronic Kidney Disease.

  Mima A. Mima A. Adv Ther. 2021 May;38(5):2201-2212. doi: 10.1007/s12325-021-01735-5. Epub 2021 Apr 16. Adv Ther. 2021. PMID: 33860925 Review.